EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim By Ogkologos - September 18, 2025 197 0 Facebook Twitter Google+ Pinterest WhatsApp Vivlipeg is highly similar to the reference product Neulasta, which was authorised in the EU in 2002 Source RELATED ARTICLESMORE FROM AUTHOR Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe EMA Recommends Extension of Therapeutic Indications for Ponatinib MOST POPULAR ASCO 2023 roundup: Blood tests, drugs and exercise June 12, 2023 6 Things to Know About Regrowing and Caring for Your Hair... January 8, 2021 An Increase in Healthcare Costs Associated with the Use of Multigene... February 14, 2024 Zanidatamab Demonstrates Meaningful Clinical Benefit with a Manageable Safety Profile in... June 7, 2023 Load more HOT NEWS Shorter, More Intensive Radiation Safe after Surgery for Prostate Cancer Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with... COVID Vaccine Basics for Cancer Patients Study Shows that Disrupted Gut Bacteria May Contribute to the Spread...
